Imaging biomarkers in diabetic patients with retinal oedema treated on intravitreal anti-VEGF
- Conditions
- Health Condition 1: H357- Separation of retinal layers
- Registration Number
- CTRI/2024/04/065549
- Lead Sponsor
- K P Salve Institute of Medical Sciences and Research Centre , Nagpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients above 18 years of age, compliant for follow-up and willing to participate
2.Patients of type I and type II Diabetes mellitus presenting with diabetic macular oedema resulting in visual loss
3.Study eye having best corrected visual acuity of less than 6/12. Macular oedema defined clinically and by SD- OCT as retinal thickness of more than 250µm in the central sub-field and presence of intra or sub-retinal fluid .
4.Treatment with intravitreal bevacizumab (atleast one injection) in past 6 months.
1.Other retinal diseases which can cause macular oedema like retinal vascular disorders, choroidal neovascular membrane secondary to age related macular degeneration or any other cause, uveitis
2.Recent history of any intraocular surgery leading to macular oedema
3.Any other cause of loss of visual acuity except cataract
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method